{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:31:35Z","timestamp":1790346695432,"version":"4.1.0"},"reference-count":149,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"2115 Talent Development Program of China Agricultural University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Newcastle disease virus (NDV) is an avian pathogen with an unsegmented negative-strand RNA genome that belongs to the Paramyxoviridae family. While primarily pathogenic in birds, NDV presents no threat to human health, rendering it a safe candidate for various biomedical applications. Extensive research has highlighted the potential of NDV as a vector for vaccine development and gene therapy, owing to its transcriptional modularity, low recombination rate, and lack of a DNA phase during replication. Furthermore, NDV exhibits oncolytic capabilities, efficiently eliciting antitumor immune responses, thereby positioning it as a promising therapeutic agent for cancer treatment. This article comprehensively reviews the biological characteristics of NDV, elucidates the molecular mechanisms underlying its oncolytic properties, and discusses its applications in the fields of vaccine vector development and tumor therapy.<\/jats:p>","DOI":"10.3390\/v16060886","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T12:19:46Z","timestamp":1717417186000},"page":"886","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The Application of Newcastle Disease Virus (NDV): Vaccine Vectors and Tumor Therapy"],"prefix":"10.3390","volume":"16","author":[{"given":"Huiming","family":"Yang","sequence":"first","affiliation":[{"name":"National Key Laboratory of Veterinary Public Health Security, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China"},{"name":"Key Laboratory of Animal Epidemiology of the Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Tian","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Veterinary Public Health Security, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China"},{"name":"Key Laboratory of Animal Epidemiology of the Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Veterinary Public Health Security, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China"},{"name":"Key Laboratory of Animal Epidemiology of the Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2410-6497","authenticated-orcid":false,"given":"Ye","family":"Zhao","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Veterinary Public Health Security, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China"},{"name":"Key Laboratory of Animal Epidemiology of the Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8200-312X","authenticated-orcid":false,"given":"Guozhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Veterinary Public Health Security, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China"},{"name":"Key Laboratory of Animal Epidemiology of the Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.virusres.2014.02.016","article-title":"Newcastle disease virus: Current status and our understanding","volume":"184","author":"Ganar","year":"2014","journal-title":"Virus Res."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Burman, B., Pesci, G., and Zamarin, D. (2020). Newcastle Disease Virus at the Forefront of Cancer Immunotherapy. Cancers, 12.","DOI":"10.3390\/cancers12123552"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.virusres.2015.07.001","article-title":"The therapeutic effect of death: Newcastle disease virus and its antitumor potential","volume":"209","author":"Villar","year":"2015","journal-title":"Virus Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"102837","DOI":"10.1016\/j.isci.2021.102837","article-title":"Newcastle disease virus induced ferroptosis through nutrient deprivation and ferritinophagy in tumor cells","volume":"24","author":"Kan","year":"2021","journal-title":"iScience"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zhan, Y., Yu, S., Yang, S., Qiu, X., Meng, C., Tan, L., Song, C., Liao, Y., Liu, W., and Sun, Y. (2020). Newcastle Disease virus infection activates PI3K\/Akt\/mTOR and p38 MAPK\/Mnk1 pathways to benefit viral mRNA translation via interaction of the viral NP protein and host eIF4E. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008610"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00262-020-02495-x","article-title":"Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro","volume":"69","author":"Burke","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1128\/JVI.73.6.5001-5009.1999","article-title":"Rescue of Newcastle disease virus from cloned cDNA: Evidence that cleavability of the fusion protein is a major determinant for virulence","volume":"73","author":"Peeters","year":"1999","journal-title":"J. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1006\/viro.2000.0618","article-title":"Recovery of a virulent strain of newcastle disease virus from cloned cDNA: Expression of a foreign gene results in growth retardation and attenuation","volume":"278","author":"Krishnamurthy","year":"2000","journal-title":"Virology"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Jadhav, A., Zhao, L., Ledda, A., Liu, W., Ding, C., Nair, V.A.-O.X., and Ferretti, L. (2020). Patterns of RNA Editing in Newcastle Disease Virus Infections. Viruses, 12.","DOI":"10.3390\/v12111249"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8676","DOI":"10.1128\/JVI.77.16.8676-8685.2003","article-title":"Newcastle disease virus V protein is associated with viral pathogenesis and functions as an alpha interferon antagonist","volume":"77","author":"Huang","year":"2003","journal-title":"J. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9522","DOI":"10.1128\/JVI.77.17.9522-9532.2003","article-title":"Newcastle disease virus V protein is a determinant of host range restriction","volume":"77","author":"Park","year":"2003","journal-title":"J. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Nan, F.L., Zhang, H., Nan, W.L., Xie, C.Z., Ha, Z., Chen, X., Xu, X.H., Qian, J., Qiu, X.S., and Ge, J.Y. (2021). Lentogenic NDV V protein inhibits IFN responses and represses cell apoptosis. Vet. Microbiol., 261.","DOI":"10.1016\/j.vetmic.2021.109181"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e02087-20","DOI":"10.1128\/JVI.02087-20","article-title":"Mechanisms and consequences of Newcastle disease virus W protein subcellular localization in the nucleus or mitochondria","volume":"95","author":"Yang","year":"2021","journal-title":"J. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"86117","DOI":"10.18632\/oncotarget.13345","article-title":"Newcastle disease virus employs macropinocytosis and Rab5a-dependent intracellular trafficking to infect DF-1 cells","volume":"7","author":"Tan","year":"2016","journal-title":"Oncotarget"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/mt.2013.54","article-title":"Endocytosis of gene delivery vectors: From clathrin-dependent to lipid raft-mediated endocytosis","volume":"21","author":"Harashima","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1128\/JVI.75.4.1918-1927.2001","article-title":"Structural and functional relationship between the receptor recognition and neuraminidase activities of the Newcastle disease virus hemagglutinin-neuraminidase protein: Receptor recognition is dependent on neuraminidase activity","volume":"75","author":"Iorio","year":"2001","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"103917","DOI":"10.1016\/j.meegid.2019.103917","article-title":"Updated unified phylogenetic classification system and revised nomenclature for Newcastle disease virus","volume":"74","author":"Dimitrov","year":"2019","journal-title":"Infect. Genet. Evol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1099\/vir.0.80822-0","article-title":"Virulence of Newcastle disease virus is determined by the cleavage site of the fusion protein and by both the stem region and globular head of the haemagglutinin-neuraminidase protein","volume":"86","author":"Koch","year":"2005","journal-title":"J. Gen. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.micpath.2003.07.003","article-title":"Role of fusion protein cleavage site in the virulence of Newcastle disease virus","volume":"36","author":"Panda","year":"2004","journal-title":"Microb. Pathog."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Wang, Y., Yu, W., Huo, N., Wang, W., Guo, Y., Wei, Q., Wang, X., Zhang, S., Yang, Z., and Xiao, S.A.-O. (2017). Comprehensive analysis of amino acid sequence diversity at the F protein cleavage site of Newcastle disease virus in fusogenic activity. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183923"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1099\/vir.0.18714-0","article-title":"Effect of fusion protein cleavage site mutations on virulence of Newcastle disease virus: Non-virulent cleavage site mutants revert to virulence after one passage in chicken brain","volume":"84","author":"Hartog","year":"2003","journal-title":"J. Gen. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Schirrmacher, V. (2016). Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!. Biomedicines, 4.","DOI":"10.3390\/biomedicines4030016"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/1097-0142(196507)18:7<863::AID-CNCR2820180714>3.0.CO;2-V","article-title":"Newcastle disease virus as an antineoplastic agent","volume":"18","author":"Cassel","year":"1965","journal-title":"Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Huang, F., Dai, C., Zhang, Y., Zhao, Y., Wang, Y., and Ru, G. (2022). Development of Molecular Mechanisms and Their Application on Oncolytic Newcastle Disease Virus in Cancer Therapy. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.889403"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12935-020-01514-2","article-title":"Hexokinase inhibition using D-Mannoheptulose enhances oncolytic newcastle disease virus-mediated killing of breast cancer cells","volume":"20","author":"Hamzah","year":"2020","journal-title":"Cancer Cell Int."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Al-Shammari, A.M., Abdullah, A.H., Allami, Z.M., and Yaseen, N.Y. (2019). 2-Deoxyglucose and Newcastle Disease Virus Synergize to Kill Breast Cancer Cells by Inhibition of Glycolysis Pathway Through Glyceraldehyde3-Phosphate Downregulation. Front. Mol. Biosci., 6.","DOI":"10.3389\/fmolb.2019.00090"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0022-4804(92)90310-V","article-title":"Newcastle disease virus selectively kills human tumor cells","volume":"52","author":"Reichard","year":"1992","journal-title":"J. Surg. Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Garcia-Romero, N., Palacin-Aliana, I., Esteban-Rubio, S., Madurga, R., Rius-Rocabert, S., Carrion-Navarro, J., Presa, J., Cuadrado-Castano, S., Sanchez-Gomez, P., and Garcia-Sastre, A. (2020). Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion. Cells, 9.","DOI":"10.3390\/cells9061405"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1128\/JVI.02618-05","article-title":"Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines","volume":"80","author":"Krishnamurthy","year":"2006","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/ijc.21821","article-title":"Tumor selective replication of Newcastle disease virus: Association with defects of tumor cells in antiviral defence","volume":"119","author":"Fiola","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Schirrmacher, V. (2022). Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus. Biomedicines, 10.","DOI":"10.3390\/biomedicines10030562"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Schirrmacher, V., van Gool, S., and Stuecker, W. (2019). Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy. Biomedicines, 7.","DOI":"10.3390\/biomedicines7030066"},{"key":"ref_33","first-page":"287","article-title":"Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus","volume":"40","author":"Fournier","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_34","first-page":"971","article-title":"Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus","volume":"34","author":"Wilden","year":"2009","journal-title":"Int. J. Oncol."},{"key":"ref_35","first-page":"85","article-title":"Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis","volume":"21","author":"Washburn","year":"2002","journal-title":"Int. J. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Lenza, M.P., Atxabal, U., Oyenarte, I., Jim\u00e9nez-Barbero, J., and Ere\u00f1o-Orbea, J. (2020). Current Status on Therapeutic Molecules Targeting Siglec Receptors. Cells, 9.","DOI":"10.3390\/cells9122691"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1128\/JVI.01537-10","article-title":"Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells","volume":"85","author":"Mansour","year":"2011","journal-title":"J. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1128\/JVI.00401-09","article-title":"The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin","volume":"84","author":"Lazar","year":"2010","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/onc.2009.507","article-title":"Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus","volume":"29","author":"Puhlmann","year":"2010","journal-title":"Oncogene"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Mustafa, Z., Shamsuddin, H.S., Ideris, A., Ibrahim, R., Jaafar, H., Ali, A.M., and Abdullah, J.M. (2013). Viability reduction and Rac1 gene downregulation of heterogeneous ex-vivo glioma acute slice infected by the oncolytic Newcastle disease virus strain V4UPM. Biomed. Res. Int., 2013.","DOI":"10.1155\/2013\/248507"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41568-019-0143-7","article-title":"The broken cycle: E2F dysfunction in cancer","volume":"19","author":"Kent","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cbin.11137","article-title":"Cell death: A review of the major forms of apoptosis, necrosis and autophagy","volume":"43","year":"2019","journal-title":"Cell Biol. Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/cdd.2014.216","article-title":"Old, new and emerging functions of caspases","volume":"22","author":"Shalini","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","article-title":"BCL-2 protein family: Attractive targets for cancer therapy","volume":"28","author":"Kaloni","year":"2023","journal-title":"Apoptosis"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.virusres.2009.05.012","article-title":"Time course of Newcastle disease virus-induced apoptotic pathways","volume":"144","author":"Ravindra","year":"2009","journal-title":"Virus Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1186\/1743-422X-8-385","article-title":"The matrix (M) protein of Newcastle disease virus binds to human bax through its BH3 domain","volume":"8","author":"Molouki","year":"2011","journal-title":"Virol. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1158\/1535-7163.MCT-14-0913","article-title":"Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models","volume":"14","author":"Ayllon","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.4161\/cbt.29686","article-title":"Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy","volume":"15","author":"Bai","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13287-016-0414-0","article-title":"Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL","volume":"7","author":"Kazimirsky","year":"2016","journal-title":"Stem Cell Res. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s13402-015-0229-5","article-title":"Human renal carcinoma cells respond to Newcastle disease virus infection through activation of the p38 MAPK\/NF-\u03baB\/I\u03baB\u03b1 pathway","volume":"38","author":"Ong","year":"2015","journal-title":"Cell. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s41419-019-2128-6","article-title":"eIF2\u03b1-CHOP-BCl-2\/JNK and IRE1\u03b1-XBP1\/JNK signaling promote apoptosis and inflammation and support the proliferation of Newcastle disease virus","volume":"10","author":"Li","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.1128\/JVI.00241-06","article-title":"Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death","volume":"80","author":"Elankumaran","year":"2006","journal-title":"J. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/viro.2002.1413","article-title":"Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus","volume":"297","author":"Zeng","year":"2002","journal-title":"Virology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"43201","DOI":"10.18632\/oncotarget.17970","article-title":"RIP1 is a central signaling protein in regulation of TNF-\u03b1\/TRAIL mediated apoptosis and necroptosis during Newcastle disease virus infection","volume":"8","author":"Liao","year":"2017","journal-title":"Oncotarget"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3892\/ijmm.2013.1244","article-title":"Newcastle disease virus Malaysian strain AF2240 induces apoptosis in MCF-7 human breast carcinoma cells at an early stage of the virus life cycle","volume":"31","author":"Ghrici","year":"2013","journal-title":"Int. J. Mol. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3390\/v6020856","article-title":"Anti-tumor effects of an oncolytic adenovirus expressing hemagglutinin-neuraminidase of Newcastle disease virus in vitro and in vivo","volume":"6","author":"He","year":"2014","journal-title":"Viruses"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1743-422X-9-179","article-title":"NDV-induced apoptosis in absence of Bax; evidence of involvement of apoptotic proteins upstream of mitochondria","volume":"9","author":"Molouki","year":"2012","journal-title":"Virol. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jcb.28118","article-title":"NDV-D90 inhibits 17\u03b2-estradiol-mediated resistance to apoptosis by differentially modulating classic and nonclassic estrogen receptors in breast cancer cells","volume":"122","author":"Shan","year":"2021","journal-title":"J. Cell Biochem."},{"key":"ref_59","first-page":"4522","article-title":"Overexpression of p53 delivered using recombinant NDV induces apoptosis in glioma cells by regulating the apoptotic signaling pathway","volume":"15","author":"Fan","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.vetmic.2018.11.017","article-title":"High level expression of ISG12(1) promotes cell apoptosis via mitochondrial-dependent pathway and so as to hinder Newcastle disease virus replication","volume":"228","author":"Li","year":"2019","journal-title":"Vet. Microbiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13567-018-0599-6","article-title":"Newcastle disease virus V protein inhibits apoptosis in DF-1 cells by downregulating TXNL1","volume":"49","author":"Wang","year":"2018","journal-title":"Vet. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1016\/j.jmb.2020.01.017","article-title":"Autophagy as a Cellular Stress Response Mechanism in the Nervous System","volume":"432","author":"Peker","year":"2020","journal-title":"J. Mol. Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/cr.2013.166","article-title":"Autophagy regulation by nutrient signaling","volume":"24","author":"Russell","year":"2014","journal-title":"Cell Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00705-012-1270-6","article-title":"Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication","volume":"157","author":"Meng","year":"2012","journal-title":"Arch. Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"E313","DOI":"10.1002\/ijc.29202","article-title":"Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death","volume":"136","author":"Koks","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1128\/JVI.01849-13","article-title":"Autophagy benefits the replication of Newcastle disease virus in chicken cells and tissues","volume":"88","author":"Sun","year":"2014","journal-title":"J. Virol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"24721","DOI":"10.1038\/srep24721","article-title":"Newcastle disease virus NP and P proteins induce autophagy via the endoplasmic reticulum stress-related unfolded protein response","volume":"6","author":"Cheng","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.vetmic.2019.01.002","article-title":"Syncytia generated by hemagglutinin-neuraminidase and fusion proteins of virulent Newcastle disease virus induce complete autophagy by activating AMPK-mTORC1-ULK1 signaling","volume":"230","author":"Ren","year":"2019","journal-title":"Vet. Microbiol."},{"key":"ref_69","first-page":"924","article-title":"Recombinant Newcastle disease virus (rL-RVG) triggers autophagy and apoptosis in gastric carcinoma cells by inducing ER stress","volume":"6","author":"Bu","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.21037\/tcr-20-1205","article-title":"Recombinant virus expressing hIFN-\u03bb1 (rL-hIFN-\u03bb1) has important effects on endoplasmic reticulum stress, autophagy and apoptosis in small cell lung cancer","volume":"9","author":"Yan","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41568-020-00312-2","article-title":"Endoplasmic reticulum stress signals in the tumour and its microenvironment","volume":"21","author":"Chen","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ymeth.2014.11.021","article-title":"LC3- and p62-based biochemical methods for the analysis of autophagy progression in mammalian cells","volume":"75","author":"Jiang","year":"2015","journal-title":"Methods"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1080\/15548627.2021.1990515","article-title":"Newcastle disease virus degrades SIRT3 via PINK1-PRKN-dependent mitophagy to reprogram energy metabolism in infected cells","volume":"18","author":"Gong","year":"2022","journal-title":"Autophagy"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2011.11.008","article-title":"Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo","volume":"317","author":"Meng","year":"2012","journal-title":"Cancer Lett."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"73981","DOI":"10.18632\/oncotarget.18169","article-title":"Newcastle disease virus-induced autophagy mediates antiapoptotic signaling responses in vitro and in vivo","volume":"8","author":"Kang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-981-15-0602-4_5","article-title":"Beclin 1, Bcl-2 and Autophagy","volume":"1206","author":"Xu","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"8108","DOI":"10.1128\/JVI.00211-09","article-title":"Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase","volume":"83","author":"Jarahian","year":"2009","journal-title":"J. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.4049\/jimmunol.170.4.1814","article-title":"TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus","volume":"170","author":"Washburn","year":"2003","journal-title":"J. Immunol."},{"key":"ref_79","first-page":"363","article-title":"Newcastle disease virus activates macrophages for anti-tumor activity","volume":"16","author":"Schirrmacher","year":"2000","journal-title":"Int. J. Oncol."},{"key":"ref_80","first-page":"1180","article-title":"Dendritic cells loaded with the lysate of tumor cells infected with Newcastle Disease Virus trigger potent anti-tumor immunity by promoting the secretion of IFN-\u03b3 and IL-2 from T cells","volume":"16","author":"Zhao","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1128\/JVI.01553-09","article-title":"Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy","volume":"84","author":"Elankumaran","year":"2010","journal-title":"J. Virol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.0105-2896.2009.00870.x","article-title":"The CD8+ dendritic cell subset","volume":"234","author":"Shortman","year":"2010","journal-title":"Immunol. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/cgt.2013.78","article-title":"Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection","volume":"21","author":"Buijs","year":"2014","journal-title":"Cancer Gene Ther."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Hu, Z., Ni, J., Cao, Y., and Liu, X. (2020). Newcastle Disease Virus as a Vaccine Vector for 20 Years: A Focus on Maternally Derived Antibody Interference. Vaccines, 8.","DOI":"10.3390\/vaccines8020222"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Kim, S.H., and Samal, S.K. (2019). Innovation in Newcastle Disease Virus Vectored Avian Influenza Vaccines. Viruses, 11.","DOI":"10.3390\/v11030300"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Fulber, J.P.C., and Kamen, A.A. (2022). Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use. Viruses, 14.","DOI":"10.3390\/v14050975"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Bello, M.B., Yusoff, K., Ideris, A., Hair-Bejo, M., Jibril, A.H., Peeters, B.P.H., and Omar, A.R. (2020). Exploring the Prospects of Engineered Newcastle Disease Virus in Modern Vaccinology. Viruses, 12.","DOI":"10.3390\/v12040451"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Saikia, D.P., Yadav, K., Pathak, D.C., Ramamurthy, N., D\u2019Silva, A.L., Marriappan, A.K., Ramakrishnan, S., Vakharia, V.N., Chellappa, M.M., and Dey, S. (2019). Recombinant Newcastle Disease Virus (NDV) Expressing Sigma C Protein of Avian Reovirus (ARV) Protects against Both ARV and NDV in Chickens. Pathogens, 8.","DOI":"10.3390\/pathogens8030145"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13567-019-0631-5","article-title":"Development of a recombinant Newcastle disease virus-vectored vaccine for infectious bronchitis virus variant strains circulating in Egypt","volume":"50","author":"Abozeid","year":"2019","journal-title":"Vet. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"11951","DOI":"10.1038\/s41598-018-30356-2","article-title":"A Recombinant Newcastle Disease Virus (NDV) Expressing S Protein of Infectious Bronchitis Virus (IBV) Protects Chickens against IBV and NDV","volume":"8","author":"Shirvani","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Zeng, Z., He, Y., Wang, Z., Yao, L., Li, L., Shang, Y., Wang, H., Zhang, R., Shao, H., and Luo, Q. (2023). Characterization of a Recombinant Thermostable Newcastle Disease Virus (NDV) Expressing Glycoprotein gB of Infectious Laryngotracheitis Virus (ILTV) Protects Chickens against ILTV Challenge. Viruses, 15.","DOI":"10.3390\/v15020500"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Qiao, Q., Song, M., Song, C., Zhang, Y., Wang, X., Huang, Q., Wang, B., Yang, P., Zhao, S., and Li, Y. (2021). Single-Dose Vaccination of Recombinant Chimeric Newcastle Disease Virus (NDV) LaSota Vaccine Strain Expressing Infectious Bursal Disease Virus (IBDV) VP2 Gene Provides Full Protection against Genotype VII NDV and IBDV Challenge. Vaccines, 9.","DOI":"10.3390\/vaccines9121483"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Sun, W.Y., Cao, X.L., Wang, Y.X., Guo, X.C., Liu, J.M., Xue, Z.Q., Li, H.J., Wang, W., Zhang, T.T., and Li, Q. (2024). Development and evaluation of a bivalent vaccine based on recombinant newcastle disease virus expressing infectious bursal disease virus VP2L-CH3-CH4 in SPF chickens. Vet. Microbiol., 288.","DOI":"10.1016\/j.vetmic.2023.109950"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.vaccine.2020.01.006","article-title":"Protection of chickens against hepatitis-hydropericardium syndrome and Newcastle disease with a recombinant Newcastle disease virus vaccine expressing the fowl adenovirus serotype 4 fiber-2 protein","volume":"38","author":"Tian","year":"2020","journal-title":"Vaccine"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.vetmic.2018.03.027","article-title":"Recombinant Newcastle disease virus (NDV) expressing Duck Tembusu virus (DTMUV) pre-membrane and envelope proteins protects ducks against DTMUV and NDV challenge","volume":"218","author":"Sun","year":"2018","journal-title":"Vet. Microbiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.virusres.2015.04.006","article-title":"Generation and evaluation of a recombinant genotype VII Newcastle disease virus expressing VP3 protein of Goose parvovirus as a bivalent vaccine in goslings","volume":"203","author":"Wang","year":"2015","journal-title":"Virus Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.3382\/ps\/pez255","article-title":"Generation and evaluation of a recombinant goose origin Newcastle disease virus expressing Cap protein of goose origin avastrovirus as a bivalent vaccine in goslings","volume":"98","author":"Xu","year":"2019","journal-title":"Poult. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1007\/s00705-019-04425-4","article-title":"Evaluation of surface glycoproteins of classical swine fever virus as immunogens and reagents for serological diagnosis of infections in pigs: A recombinant Newcastle disease virus approach","volume":"164","author":"Kumar","year":"2019","journal-title":"Arch. Virol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Zhang, H., Nan, F., Li, Z., Zhao, G., Xie, C., Ha, Z., Zhang, J., Han, J., Xiao, P., and Zhuang, X. (2019). Construction and immunological evaluation of recombinant Newcastle disease virus vaccines expressing highly pathogenic porcine reproductive and respiratory syndrome virus GP3\/GP5 proteins in pigs. Vet. Microbiol., 239.","DOI":"10.1016\/j.vetmic.2019.108490"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00705-016-3078-2","article-title":"Characterization of a recombinant Newcastle disease virus expressing the glycoprotein of bovine ephemeral fever virus","volume":"162","author":"Zhang","year":"2017","journal-title":"Arch. Virol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/j.vaccine.2015.03.091","article-title":"Recombinant Newcastle disease viral vector expressing hemagglutinin or fusion of canine distemper virus is safe and immunogenic in minks","volume":"33","author":"Ge","year":"2015","journal-title":"Vaccine"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"8241","DOI":"10.1128\/JVI.00519-11","article-title":"Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats","volume":"85","author":"Ge","year":"2011","journal-title":"J. Virol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"791764","DOI":"10.3389\/fimmu.2021.791764","article-title":"Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats","volume":"12","author":"Tcheou","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Jung, B.K., An, Y.H., Jang, J.J., Jeon, J.H., Jang, S.H., and Jang, H. (2022). The human ACE-2 receptor binding domain of SARS-CoV-2 express on the viral surface of the Newcastle disease virus as a non-replicating viral vector vaccine candidate. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0263684"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1007\/s00705-021-05234-4","article-title":"Heterologous prime-boost regimens with HAdV-5 and NDV vectors elicit stronger immune responses to Ebola virus than homologous regimens in mice","volume":"166","author":"Zhao","year":"2021","journal-title":"Arch. Virol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1128\/JVI.02847-15","article-title":"Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins","volume":"90","author":"Khattar","year":"2016","journal-title":"J. Virol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.vaccine.2019.11.088","article-title":"Evaluation of Japanese encephalitis virus E and NS1 proteins immunogenicity using a recombinant Newcastle disease virus in mice","volume":"38","author":"Nath","year":"2020","journal-title":"Vaccine"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Viktorova, E.G., Khattar, S.K., Kouiavskaia, D., Laassri, M., Zagorodnyaya, T., Dragunsky, E., Samal, S., Chumakov, K., and Belov, G.A. (2018). Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis. J. Virol., 92.","DOI":"10.1128\/JVI.00976-18"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00109-010-0605-6","article-title":"Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer","volume":"88","author":"Song","year":"2010","journal-title":"J. Mol. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3892\/or.2016.4925","article-title":"Genetically engineered Newcastle disease virus expressing human interferon-\u03bb1 induces apoptosis in gastric adenocarcinoma cells and modulates the Th1\/Th2 immune response","volume":"36","author":"Bu","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3892\/mmr.2014.2657","article-title":"Apoptotic induction of lung adenocarcinoma A549 cells infected by recombinant RVG Newcastle disease virus (rL-RVG) in vitro","volume":"11","author":"Yan","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_113","first-page":"3612","article-title":"Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy","volume":"5","author":"Hu","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.sjbs.2019.04.015","article-title":"Oncolytic Newcastle disease virus reduces growth of cervical cancer cell by inducing apoptosis","volume":"27","author":"Keshavarz","year":"2020","journal-title":"Saudi J. Biol. Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1111\/jcmm.15089","article-title":"Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells","volume":"24","author":"Wang","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.12998\/wjcc.v7.i16.2143","article-title":"Application of Newcastle disease virus in the treatment of colorectal cancer","volume":"7","author":"Song","year":"2019","journal-title":"World J. Clin. Cases"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Abdullah, J.M., Mustafa, Z., and Ideris, A. (2014). Newcastle disease virus interaction in targeted therapy against proliferation and invasion pathways of glioblastoma multiforme. Biomed. Res. Int., 2014.","DOI":"10.1155\/2014\/386470"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Wu, Y.-Y., Sun, T.-K., Chen, M.-S., Munir, M., and Liu, H.-J. (2023). Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response. Front. Cell. Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1142172"},{"key":"ref_119","first-page":"635","article-title":"Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68\/H)","volume":"19","author":"Csatary","year":"1999","journal-title":"Anticancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2002.08.042","article-title":"Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers","volume":"20","author":"Pecora","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/cgt.2008.31","article-title":"Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors","volume":"15","author":"Yaacov","year":"2008","journal-title":"Cancer Gene Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/978-1-59745-561-9_30","article-title":"Newcastle disease virus: A promising vector for viral therapy, immune therapy, and gene therapy of cancer","volume":"542","author":"Schirrmacher","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM196409242711302","article-title":"Observations on the repeated administration of viruses to a patient with acute leukemia","volume":"24","author":"Wheelock","year":"1964","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF02987752","article-title":"A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate","volume":"9","author":"Cassel","year":"1992","journal-title":"Med. Oncol. Tumor Pharmacother."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/BF03401771","article-title":"A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire","volume":"4","author":"Batliwalla","year":"1998","journal-title":"Mol. Med."},{"key":"ref_126","first-page":"619","article-title":"Attenuated veterinary virus vaccine for the treatment of cancer","volume":"17","author":"Csatary","year":"1993","journal-title":"Cancer Detect. Prev."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/B:NEON.0000021735.85511.05","article-title":"MTH-68\/H oncolytic viral treatment in human high-grade gliomas","volume":"67","author":"Csatary","year":"2004","journal-title":"J. Neurooncol"},{"key":"ref_128","first-page":"618","article-title":"Overview of phase I studies of intravenous administration of PV701, an oncolytic virus","volume":"5","author":"Lorence","year":"2003","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ymthe.2005.08.016","article-title":"Phase I\/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme","volume":"13","author":"Freeman","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.actatropica.2018.04.007","article-title":"Newcastle disease virus strain AF2240 as an oncolytic virus: A review","volume":"183","author":"Kalyanasundram","year":"2018","journal-title":"Acta Trop."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s12935-020-01372-y","article-title":"Cytotoxicity study of the interleukin-12-expressing recombinant Newcastle disease virus strain, rAF-IL12, towards CT26 colon cancer cells in vitro and in vivo","volume":"20","author":"Najmuddin","year":"2020","journal-title":"Cancer Cell Int."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e9761","DOI":"10.7717\/peerj.9761","article-title":"Oncolytic effects of the recombinant Newcastle disease virus, rAF-IL12, against colon cancer cells in vitro and in tumor-challenged NCr-Foxn1nu nude mice","volume":"8","author":"Amin","year":"2020","journal-title":"PeerJ"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1200\/JCO.1997.15.4.1354","article-title":"Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer","volume":"15","author":"Ahlert","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF00184874","article-title":"Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines","volume":"13","author":"Kirchner","year":"1995","journal-title":"World J. Urol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"8057","DOI":"10.1158\/0008-5472.CAN-04-1545","article-title":"Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells","volume":"64","author":"Karcher","year":"2004","journal-title":"Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1200\/JCO.2004.09.038","article-title":"Antitumor vaccination of patients with glioblastoma multiforme: A pilot study to assess feasibility, safety, and clinical benefit","volume":"22","author":"Steiner","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_137","first-page":"21","article-title":"Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma","volume":"2","author":"Ockert","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-008-0526-1","article-title":"Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: Results of a prospective randomized trial","volume":"58","author":"Schulze","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3748\/wjg.v9.i3.495","article-title":"Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract","volume":"9","author":"Liang","year":"2003","journal-title":"World J. Gastroenterol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3892\/ijo.2014.2692","article-title":"Strong T-cell costimulation can reactivate tumor antigen-specific T cells in late-stage metastasized colorectal carcinoma patients: Results from a phase I clinical study","volume":"46","author":"Schirrmacher","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s12032-023-02002-z","article-title":"Investigation of oncolytic effect of recombinant Newcastle disease virus in primary and metastatic oral melanoma","volume":"40","author":"Numpadit","year":"2023","journal-title":"Med. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"Np83","DOI":"10.1177\/1533034615601521","article-title":"Recombinant Newcastle Disease Virus Encoding IL-12 and\/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy","volume":"15","author":"Ren","year":"2016","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/cas.13468","article-title":"Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy","volume":"109","author":"Xu","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.omto.2019.06.001","article-title":"Tumor Cells Modified with Newcastle Disease Virus Expressing IL-24 as a Cancer Vaccine","volume":"14","author":"Xu","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e000330","DOI":"10.1136\/jitc-2019-000330","article-title":"A recombinant oncolytic Newcastle virus expressing MIP-3\u03b1 promotes systemic antitumor immunity","volume":"8","author":"Huang","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41434-021-00256-8","article-title":"Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy","volume":"30","author":"Tian","year":"2023","journal-title":"Gene Ther."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Nettelbeck, D.M., Leber, M.F., Altomonte, J., Angelova, A., Beil, J., Berchtold, S., Delic, M., Eberle, J., Ehrhardt, A., and Engeland, C.E. (2021). Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies. Viruses, 13.","DOI":"10.3390\/v13081420"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ebiom.2019.10.032","article-title":"Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma","volume":"49","author":"Vijayakumar","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","article-title":"Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody","volume":"3","author":"Stewart","year":"2015","journal-title":"Cancer Immunol. Res."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/6\/886\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:51:22Z","timestamp":1760107882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/6\/886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":149,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["v16060886"],"URL":"https:\/\/doi.org\/10.3390\/v16060886","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}